Friday, May 14th, 2010
UK-based venture and growth capital funds EV and Catapult Venture announced that they have provided funding to Liverpool-based molecular diagnostics company, Biofortuna Limited.
The funding will be used to launch the company’s first diagnostic genotyping products and to allow it to continue development of its future product pipeline.
The management team is led by CEO Mike Bunce [...]
Monday, November 16th, 2009
Lab901 (Edinburgh, UK) and Biofortuna (Liverpool, UK) today announced that they will collaborate on the launch of an automated PCR based diagnostics system for the rapid detection of certain HLA-related diseases such as Coeliac disease. Lab901 will be optimising its automated ScreenTape® PCR diagnostics platform for use with Biofortuna’s range of multiplex PCR diagnostics kits [...]
Friday, November 13th, 2009
Biofortuna were today approved by Lloyds Register Quality Assurance for the design and manufacture of genotyping and phenotyping in-vitro diagnostic products which enables us to sell CE marked products.
The rapid progress in quality management is testament to the dedication and skill of our quality team and our consultant Dave Ashworth from Flintloque Management Systems.
(See also [...]
Friday, November 13th, 2009
Over 200 people from the Northwest’s biomedical sector gathered last night (Thursday 12th November) at the prestigious annual Northwest Biomedical Awards at Mere Golf and Country Club. The awards, organised by Bionow, the Northwest Regional Development Agency’s (NWDA) biomedical cluster support group, were a resounding success and showcased the very best of the region’s world [...]
Wednesday, March 4th, 2009
Biofortuna secure an offer of £94,558 from the Northwest Development Agency in a grant for Research & Development. The grant will enable Biofortuna to develop a novel DNA genotyping method that has the potential to allow healthcare professionals to look at multiple gene mutations simultaneously in one rapid test.
(Also featured in the Bionow May newsletter)
Wednesday, February 4th, 2009
Mark Reardon and Andy Bonner join Biofortuna as Software Development manager and Operations manager respectively.
(Also featured on the Merseybio website)
Thursday, December 4th, 2008
Following successful proof of concept work AFM through the Liverpool Seed Fund inject £450,000 into Biofortuna in two rounds of funding to complete the proof of concept and commercialisation phases.
(Also featured on the Liverpool Daily Post website)
Friday, July 4th, 2008
Biofortuna founding directors David Charvill and Ben Passey begin setting up laboratories at the MerseyBio incubator facility. Ben Passey, said “The MerseyBIO Incubator is a fantastic resource for local start-up companies. It offers flexible, affordable lab and office space as well as great support services which really help fledgling companies get off to a great [...]
Wednesday, June 4th, 2008
Biofortuna secures an initial round of funding from the Merseyside Special Investment Fund via Liverpool Ventures.
The Biofortuna team is made up of founder directors Mike Bunce, David Charvill and Ben Passey, previously of Wirral based Invitrogen, formerly Dynal Biotech Ltd.
